Higher disease activity is linked to faster eGFR decline and a greater risk for significant kidney dysfunction in RA.
The latest CorEvitas registry – the company’s 11th independent registry – will allow the prospective evaluation of adolescent AD patients to better understand the disease and the treatment pathway. It ...
Thermo Fisher's business strategy involves expansion through strategic acquisition of technologies and businesses that boost ...
Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the international CorEvitas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback